The New England journal of medicine, 2019-09, Vol.381 (11), p.1001-1010
2019
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
- Ist Teil von
- The New England journal of medicine, 2019-09, Vol.381 (11), p.1001-1010
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- This phase 3, randomized trial in China compared the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, with placebo for anemia in patients with CKD who were not undergoing dialysis. Roxadustat was superior to placebo in increasing and maintaining hemoglobin levels.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1813599Titel-ID: cdi_proquest_journals_2288822410
- Format
- –
- Schlagworte
- Acetic acid, Acidosis, Acidosis - chemically induced, Adult, Aged, Anemia, Anemia - drug therapy, Anemia - etiology, Cardiovascular disease, Care and treatment, Cholesterol, Cholesterol - blood, Complications and side effects, Dialysis, Double-Blind Method, Erythropoiesis, Erythropoietin, Female, Glycine - adverse effects, Glycine - analogs & derivatives, Glycine - therapeutic use, Heart failure, Hematinics - adverse effects, Hematinics - therapeutic use, Hemodialysis, Hemoglobin, Hemoglobins - analysis, Hepcidin, Homeostasis, Humans, Hyperkalemia, Hyperkalemia - chemically induced, Hypoxia-Inducible Factor-Proline Dioxygenases - antagonists & inhibitors, Hypoxia-inducible factors, Iron, Isoquinolines - adverse effects, Isoquinolines - therapeutic use, Kidney diseases, Male, Metabolic acidosis, Metabolism, Middle Aged, Patients, Prolyl hydroxylase, Renal Insufficiency, Chronic - blood, Renal Insufficiency, Chronic - complications, Risk factors